Your browser doesn't support javascript.
loading
[Disease-modifying Drugs in Alzheimer's Disease: Indications and Efficacy Evaluation].
Iwata, Atsushi.
Afiliação
  • Iwata A; Tokyo Metropolitan Institute for Geriatrics and Gerontology.
Brain Nerve ; 76(9): 1005-1009, 2024 Sep.
Article em Ja | MEDLINE | ID: mdl-39251219
ABSTRACT
The launch of lecanemab (an anti-Aß antibody) has introduced a new treatment for Alzheimer's disease. In contrast to conventional therapeutic approaches to dementia, this drug requires new concepts in diagnosis, evaluation, and adverse effects. Specifically, evaluation of the efficacy of lecanemab is extremely important because this drug does not prevent but only slows the rate of disease progression. In this report, I have discussed future issues, including my personal viewpoint and also described the guidelines for promotion of the optimal use of lecanemab issued by the Ministry of Health, Labour, and Welfare.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Limite: Humans Idioma: Ja Revista: Brain Nerve Assunto da revista: CEREBRO / NEUROLOGIA Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Limite: Humans Idioma: Ja Revista: Brain Nerve Assunto da revista: CEREBRO / NEUROLOGIA Ano de publicação: 2024 Tipo de documento: Article
...